دورية أكاديمية
أعرض في EDS

Toll-like receptors-2 and -9 (TLR2 and TLR9) gene polymorphism in patients with type 2 diabetes and diabetic foot.

التفاصيل البيبلوغرافية
العنوان: Toll-like receptors-2 and -9 (TLR2 and TLR9) gene polymorphism in patients with type 2 diabetes and diabetic foot.
المؤلفون: Wifi MA; Department of Internal Medicine Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo Univeristy, Cairo, Egypt., Assem M, Elsherif RH, El-Azab HA, Saif A
المصدر: Medicine [Medicine (Baltimore)] 2017 Apr; Vol. 96 (17), pp. e6760.
نوع المنشور: Journal Article; Observational Study
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Genetic Predisposition to Disease* , Polymorphism, Restriction Fragment Length*, Diabetes Mellitus, Type 2/*genetics , Diabetic Foot/*genetics , Toll-Like Receptor 2/*genetics , Toll-Like Receptor 9/*genetics, Diabetes Mellitus, Type 2/drug therapy ; Diabetic Foot/drug therapy ; Female ; Genetic Association Studies ; Genotype ; Genotyping Techniques ; Humans ; Male ; Middle Aged ; Polymerase Chain Reaction
مستخلص: Toll-like receptors (TLRs) are innate immune receptors that mediate the inflammatory response in diabetes mellitus (DM). The aim of this study is to evaluate the association of TLR2 and TLR9 gene polymorphism in patients with type 2 DM (T2DM) and diabetic foot (DF).The study included 90 subjects divided into group I (30 patients with T2DM and DF), group II (30 patients with T2DM and no evidence of DF), and group III (normal control subjects). TLR2 (1350 T/C, rs3804100) and TLR9 (1237 T/C, rs5743836) genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) technique for all subjects.There was a statistically significant difference in the distribution of TLR9-1237 T/C genotypes between groups I and II (P < .029) as well as between groups I and III (P < .001). Calculated risk estimation revealed that TLR9-1237 polymorphism conferred almost 20 times increased risk of DF disorders in T2DM (OR = 20, 95% CI = 5.38-74.30). There was no statistical difference in the distribution of TLR2-1350T/C genotypes between the 3 groups.TLR9-1237 T/C gene polymorphism may be considered as a molecular risk for DF among patients with T2DM.
References: World J Diabetes. 2014 Apr 15;5(2):219-23. (PMID: 24748934)
Ann Rheum Dis. 2007 Jul;66(7):905-9. (PMID: 17344245)
J Diabetes Complications. 2016 Jan-Feb;30(1):99-108. (PMID: 26525587)
J Korean Med Sci. 2012 Nov;27(11):1333-8. (PMID: 23166414)
J Exp Med. 2010 Dec 20;207(13):2931-42. (PMID: 21115693)
Lab Invest. 2010 Nov;90(11):1628-36. (PMID: 20733560)
J Biomed Biotechnol. 2012;2012:373945. (PMID: 23091345)
Tissue Antigens. 2005 Mar;65(3):266-70. (PMID: 15730519)
Genomics. 2003 Jan;81(1):85-91. (PMID: 12573264)
Eur J Cancer Prev. 2009 Apr;18(2):117-9. (PMID: 19337058)
J Leukoc Biol. 2001 Mar;69(3):474-81. (PMID: 11261796)
Lancet Infect Dis. 2005 Mar;5(3):156-64. (PMID: 15766650)
Int J Low Extrem Wounds. 2013 Dec;12(4):310-5. (PMID: 24214952)
Immunol Rev. 2004 Dec;202:250-65. (PMID: 15546398)
Open Dent J. 2011;5:190-4. (PMID: 22235236)
J Invest Dermatol. 2013 Apr;133(4):988-98. (PMID: 23223142)
Nat Immunol. 2001 Aug;2(8):675-80. (PMID: 11477402)
Int J Mol Med. 2013 Mar;31(3):555-60. (PMID: 23314218)
Scand J Immunol. 2012 May;75(5):517-23. (PMID: 22229967)
PLoS One. 2011;6(11):e28256. (PMID: 22132241)
Ann Hematol. 2014 Nov;93(11):1859-65. (PMID: 24912772)
FASEB J. 2004 Feb;18(2):412-4. (PMID: 14688201)
Am J Physiol Endocrinol Metab. 2007 Mar;292(3):E740-7. (PMID: 17090751)
Int Immunol. 2006 Jul;18(7):1101-13. (PMID: 16728431)
Diabetes Res Clin Pract. 2011 Aug;93(2):215-219. (PMID: 21596454)
Curr Diabetes Rev. 2012 Nov;8(6):480-8. (PMID: 22934553)
J Transl Med. 2011 Aug 21;9:139. (PMID: 21854645)
Carcinogenesis. 2009 Feb;30(2):275-81. (PMID: 19029192)
BMC Cancer. 2012 Feb 07;12:57. (PMID: 22309608)
J Diabetes Complications. 2013 Sep-Oct;27(5):417-21. (PMID: 23773694)
Nat Rev Immunol. 2004 Jul;4(7):499-511. (PMID: 15229469)
Int Wound J. 2008 Oct;5(4):530-9. (PMID: 19006574)
Physiol Rev. 2003 Jul;83(3):835-70. (PMID: 12843410)
المشرفين على المادة: 0 (TLR2 protein, human)
0 (TLR9 protein, human)
0 (Toll-Like Receptor 2)
0 (Toll-Like Receptor 9)
تواريخ الأحداث: Date Created: 20170427 Date Completed: 20170601 Latest Revision: 20220318
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC5413269
DOI: 10.1097/MD.0000000000006760
PMID: 28445304
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5964
DOI:10.1097/MD.0000000000006760